Kiniksa Pharmaceuticals International, plc (KNSA) earnings date
Mar 2, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 28 days, typically, give or take 13 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Tue, Oct 27, 2026 | before open | 27 | 8-K |
| Q2 FY2026 | Tue, Jul 28, 2026 | before open | 28 | 8-K |
| Q1 FY2026 | Tue, Apr 28, 2026 | before open | 28 | 8-K |
| Q4 FY2025 | Tue, Feb 24, 2026 | before open | 55 | 8-K |
| Q3 FY2025 | Tue, Oct 28, 2025 | before open | 28 | 8-K |
| Q2 FY2025 | Tue, Jul 29, 2025 | before open | 29 | 8-K |
| Q1 FY2025 | Tue, Apr 29, 2025 | before open | 29 | 8-K |
| Q4 FY2024 | Tue, Feb 25, 2025 | before open | 56 | 8-K |
What they guided beta
| Q3 FY2026 | "EX-99.1 2 knsa-ex99d1.htm EX-99.1 Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – London – October 27, 2026 – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company de" exhibit |
| Q3 FY2026 | "We now expect 2026 ARCALYST net sales of between $1.045 and $1.050 billion, up from our previous range of between $980 and $995 million." exhibit |
| Q3 FY2026 | "We expect data in the second half of 2027, with the goal of bringing this important treatment option to patients in the 2028/2029 timeframe." exhibit |
| Q3 FY2026 | "Kiniksa is enrolling and dosing patients in the Phase 3 pivotal trial of KPL-387 in recurrent pericarditis, PASTORALE, and expects data in the second half of 2027." exhibit |
| Q3 FY2026 | "Kiniksa expects to initiate a Phase 1 first-in-human clinical trial of KPL-1161 with a target profile of quarterly subcutaneous (SC) dosing by the end of 2026. Financial Results" exhibit |
| Q2 FY2026 | "EX-99.1 2 knsa-20260728xex99d1.htm EX-99.1 Exhibit 99.1 Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, the dose level selected for Phase 3 – – KPL-387 pivotal Phase 3 trial in recurrent pericarditis now enrolling and dosing" exhibit |
| Q2 FY2026 | "As a result, we have raised our 2026 ARCALYST net sales guidance to between $980 and $995 million,” said Sanj K." exhibit |
| Q2 FY2026 | "We expect to bring this potential additional treatment option to patients in the 2028/2029 timeframe." exhibit |
| Q2 FY2026 | "The company expects to initiate a Phase 1 first-in-human clinical trial by the end of 2026. * Reported as median (95% confidence interval). 1 Treatment Response is defined as Pain Response (NRS score ≤ 2 on the 11-point daily pericarditis pain NRS pain scale) and at least one CRP level ≤ 0.5 mg/dL within 7 days before or after the Pain Response. 2 CRP Normalization is defined as CRP ≤ 0.5 mg/dL. 2 Financial Results" exhibit |
| Q2 FY2026 | "As of June 30, 2026, Kiniksa had $525.9 million of cash, cash equivalents, and short-term investments and no debt. Financial Guidance" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/KNSA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/KNSA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/KNSA/"><img src="https://veritasdata.dev/embed/KNSA.svg" alt="KNSA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/KNSA/)
Script
<script async src="https://veritasdata.dev/embed/KNSA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/KNSA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.